Christopher Ogden is CFO at CytomX Therapeutics, Inc. (CTMX). They have made 8 open-market trades across 1 company since 2023, most recently 2026-06-15.
CIK 0001914523
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 8 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| CTMX | 295,324 | $673K |
Shares reported on the most recent Form 4, priced at the 2026-06-17 close.
Counted per filing, not per execution lot — a purchase filled in several tranches is one decision.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| CTMX | SELL | 2026-06-15 | 2026-06-17 | $3.05 | $5K | +23.0% | +18.4% | -11.5% |
| CTMX | SELL | 2026-03-17 | 2026-03-19 | $6.42 | $248K | +1.7% | +6.0% | -36.0% |
| CTMX | SELL | 2025-06-13 | 2025-06-17 | $2.72 | $33K | -5.0% | -0.4% | -16.7% |
| CTMX | SELL | 2025-03-18 | 2025-03-20 | $0.60 | $5K | -10.1% | +16.3% | +227.1% |
| CTMX | SELL | 2024-08-20 | 2024-08-22 | $1.23 | $2K | +5.0% | -3.4% | -26.9% |
| CTMX | SELL | 2024-03-19 | 2024-03-21 | $2.09 | $6K | -2.7% | -24.4% | -42.1% |
| CTMX | SELL | 2023-12-20 | 2023-12-22 | $1.38 | $3K | +3.4% | +11.6% | +53.4% |
| CTMX | SELL | 2023-03-16 | 2023-03-20 | $1.98 | $1K | -20.0% | -8.1% | -17.3% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.